Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 150.00
High: 150.00
Low: 150.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: Everyman revenue doubles; Aeorema in interim profit

Fri, 25th Mar 2022 13:21

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Everyman Media Group PLC - London-based cinema company - Revenue doubles to GBP49.0 million in 2021 from GBP24.2 million in 2020 - though remains below pre-pandemic level of GBP65.0 million - and pretax loss narrows to GBP5.4 million from GBP21.8 million. Says 2021 included normal trading with full capacity for 24 weeks, nine weeks of reduced capacity due to Covid-19 restrictions, and 19 weeks full closure. Admissions increased 67% to 2.0 million. Says since re-opening, it has delivered positive adjusted profit every month as well as admission levels and average spends being higher than expectations. "We are optimistic for the coming year, with customers continuing to appreciate the unique Everyman experience. Alongside this, a strong and varied film slate is anticipated, with a good mix of both the major releases and the well-watched independent films that our customers enjoy. So far in 2022 admissions momentum has continued," says Everyman.

----------

Aeorema Communications PLC - London-based live events agency - Revenue for half-year to December 31 jumps to GBP4.9 million from GBP1.7 million year-on-year, and swings to pretax profit of GBP255,677 from loss of GBP287,676. Says this is first profitable interim period "for a number of years". "During the period under review, we have received an unprecedented demand for our bespoke services from a wide range of blue-chip clients across a number of industries." firm says, adding consultancy services offering also boosted performance. Has strong outlook for second half.

----------

Faron Pharmaceuticals Oy - Turku, Finland-based clinical-stage biopharmaceutical company - Loss for 2021 widens to EUR21.2 million from EUR16.9 million in 2020, with no revenue recorded in either period. Flags progress across pipeline programmes during the year, including for Bexmarilimab, a novel precision cancer immunotherapy candidate, and for Traumakine, with dosing started in a trial investigating the treatment in hospitalised Covid-19 patients. "Despite the difficult funding environment due to Covid-19, Faron has successfully secured further investment over the period to progress its pipeline. This is testament not only to the potential of our product candidates but also to the expertise and credibility of the management team," firm says.

----------

VinaCapital Vietnam Opportunity Fund Ltd - Vietnam-focused investor - Net asset value per share USD8.54 at end of December, with total return over the half-year 6.9%. NAV per share stood at USD8.07 at June 30. Says investment manager delivered "respectable" results amid volatility in second half of 2021. "In 2022 to date, the Vietnam market has shown some resilience against the background of an increasingly volatile investment market in more developed countries and, most recently, the turmoil following Russia's invasion of Ukraine," it says. On Thursday declared dividend of 8.0 cents. "Although the board remains committed to its policy of distributing dividends representing approximately 1% of net asset value each half year, given the current global uncertainties, the board has decided not to increase the dividend at this stage but will review the dividend again once the results for the full year are known," it says.

----------

GCM Resources PLC - Phulbari coal and power project in north-west Bangladesh - Says performance over six months to December 31 was hindered by pandemic as "Bangladesh, unlike most of Europe, did not move from the rolling lock-downs until late August and the return to 'business as usual' has been slow." Pretax loss for half slims to GBP763,000 from GBP1.1 million, however. "Over the next 12 months, the company will seek to further strengthen GCM's financial position and provide future funding, and the directors remain confident that sufficient funding will be obtained as and when required," it says.

----------

Secured Income Fund PLC - specialist secured-lending income investment trust - Net asset value per share 25.10 pence at end of December, down from 36.28p at end of June and 78.26p a year ago. Says it continued to focus on returning capital to shareholders in "efficiently and in a timely manner", after wind-down proposals were adopted in September 2020. "The primary focus remains unchanged in the managed wind-down, achieving a balance between maximising the value received from the remaining assets and making timely returns of capital to Shareholders. The board expects to have realised most of the remaining portfolio within the next two years," it says.

----------

UK Oil & Gas PLC - London-based oil and gas company focused on operations in the UK - Revenue for financial year ended September 30 jumps to GBP1.6 million from GBP908,000 the year before, and pretax loss slims to GBP4.8 million from GBPP20.9 million. Impairment expense reduces to GBP1.5 million from GBP10.7 million. Notes oil and gas industry rebounded strongly in 2021, with oil prices hitting their highest levels in six years. "At the time of writing, Brent prices have surpassed USD100 per barrel, with concerns about the omicron variant of Covid-19 easing. This optimism has been tempered by the worrying events in Ukraine which will have a direct impact on our future security," it says. Predicts "busy" 2022. It adds: "The company is reviewing the potential acquisition of further new international producing oil and gas properties which have the potential to deliver potentially significant short term cash flow. These assets also have the potential to become self-funding relatively quickly."

----------

BMO Private Equity Trust PLC - investor in unlisted companies and specialist private equity funds - Net asset value per share 640.30p at December 31, reflecting total return for the year of 36%. This beats FTSE All-Share Index which returns 18% over the same period. NAV per share stood at 486.17p at end of 2020. Recommends quarterly dividend of 5.65p, taking total for year to 20.04p, equivalent to yield of 4.1%. Says 2021 was "outstanding" year for firm. "The principal drivers of this year's returns have been ongoing recovery from the pandemic and an exceptionally strong flow of realisations across the breadth of the portfolio. Whilst there was clearly some catch up with deals postponed from the previous year, there has also been a genuine increase in the proportion of investment capital allocated towards private equity in general and this has underpinned the strong market," firm says.

----------

Parkmead Group PLC - Netherlands and UK-focused gas explorer based in London - Revenue for six months to end of December grows to GBP4.6 million from GBP1.5 million year-on-year. Swings to pretax profit of GBP1.3 million from loss of GBP1.4 million. "We have delivered a tripling of our revenue, led by our high-quality Dutch assets and the significant rise in gas prices. The innovative royalty deal we completed last summer is proving to be highly advantageous and is adding considerable value to Parkmead. Parkmead is 100% unhedged and is directly benefitting from these additional gas sales at higher prices," says Executive Chair Tom Cross. Says current gas environment provides "excellent opportunities". Adds it is maintaining appetite for acquisitions into 2022 and is mulling a number of opportunities.

----------

Triple Point Social Housing REIT PLC - London-based real estate investment trust - EPRA net tangible assets per share rises to 108.27p at end of December from 106.42p a year before. Portfolio value rises to GBP642.0 million from GBP571.5 million on IFRS basis, and portfolio's total annualised rental income was GBP35.8 million as at December 31 versus GBP31.6 million a year ago. Paid dividends totalling 5.20p for the year, in line with target.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
6 Nov 2023 11:03

IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.

Read more
6 Nov 2023 10:31

Faron reveals details of next stage of bexmarilimab study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study investigating bexmarilimab in combination with standard of care, would focus on hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS).

Read more
30 Oct 2023 15:56

TRADING UPDATES: Bezant optimistic after Hope & Gorob estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
11 Oct 2023 14:53

Faron Pharmaceuticals upbeat on latest data in blood cancer trials

(Sharecast News) - Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two 'BEXMAB' study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) treatments on Wednesday.

Read more
11 Oct 2023 14:01

IN BRIEF: Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Says Bexmarilimab study shows 50% remission rate for patients with in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Says eight of eleven patients were complete responders or complete responders with incomplete blood recovery. Adds Bexmarilimab continues to be well-tolerated at all tested dose levels, as no dose-limiting toxicity has been observed.

Read more
21 Sep 2023 14:45

Faron Pharmaceuticals names interim chief medical officer

(Sharecast News) - Cancer immunotherapy-focussed biopharmaceutical firm Faron Pharmaceuticals named Dr Birge Berns as its interim chief medical officer on Thursday, with the transition becoming effective on 22 September, with Dr Berns operating from the UK.

Read more
21 Sep 2023 12:12

TRADING UPDATES: Faron appoints Birge Berns as interim medical officer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Sep 2023 15:46

UK shareholder meetings calendar - next 7 days

Monday 18 September 
Baillie Gifford US Growth Trust PLCAGM
Inteliqo LtdAGM
LendInvest PLCAGM
Rosslyn Data Technologies PLCGM re fundraise
Tuesday 19 September 
Africa Opportunity Fund LtdAGM
Aston Martin Lagonda Global Holdings PLCGM re supply arrangement with Lucid Group Inc
Augmentum Fintech PLCAGM
Beacon Rise Holdings PLCAGM
Begbies Traynor Group PLCAGM
Chill Brands Group PLCAGM
DP Aircraft I LtdAGM
Great Southern Copper PLCAGM
Manolete Partners PLCAGM
Moonpig Group PLCAGM
Oxford Instruments PLCAGM
ProCook Group PLCAGM
SRT Marine Systems PLCAGM
Unicorn Mineral Resources PLCAGM
Wednesday 20 September 
Accsys Technologies PLCAGM
Frasers Group PLCAGM
Games Workshop Group PLCAGM
Hidong Estate PLCAGM
IG Group Holdings PLCAGM
Ilika PLCAGM
Nippon Active Value Fund PLCGM re assets rollover
Quiz PLCAGM
Seed Innovations LtdAGM
STS Global Income & Growth Trust PLCAGM
Thursday 21 September 
Ascent Resources PLCGM re audited annual accounts
Intercede Group PLCAGM
Kore Potash PLCGM re capital raise
Liontrust Asset Management PLCAGM
Mercia Asset Management PLCAGM
Molecular Energies PLCAGM
Oberon Investments Group PLCAGM
Pelatro PLCGM re AIM cancellation
Sosandar PLCAGM
Thruvision Group PLCAGM
Trakm8 Holdings PLCAGM
Van Elle Holdings PLCAGM
Friday 22 September 
Argos Resources LtdGM re members voluntary liquidation
B&M European Value Retail SAGM re appointing Lasry as director
Faron Pharmaceuticals LtdEGM re election of new board members
Stranger Holdings PLCAGM
SysGroup PLCAGM
TI Fluid Systems PLCGM re waiver resolution
Odyssean Investment Trust PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
29 Aug 2023 10:23

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
29 Aug 2023 10:15

Faron shares surge on FDA drug designation; loss widens on costs

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its interim loss widened on higher costs but saw shares soar after it gained a US Food & Drug Administration orphan drug designation for Bexmarilimab.

Read more
22 Aug 2023 15:46

UK earnings, trading statements calendar - next 7 days

Wednesday 23 August 
Angling Direct PLCTrading Statement
Costain Group PLCHalf Year Results
Thursday 24 August 
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
James Cropper PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Princess Private Equity Holding LtdHalf Year Results
Redcentric PLCFull Year Results
South32 LtdFull Year Results
Tribal Group PLCHalf Year Results
Friday 25 August 
no events scheduled 
Monday 28 August 
no events scheduled 
Tuesday 29 August 
Amaroq Minerals LtdHalf Year Results
Bunzl PLCHalf Year Results
Dalata Hotel Group PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
PureTech Health PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jul 2023 10:27

Faron Pharmaceuticals sees positive data from phase 1 BEXMAB trial

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said data from its phase 1 BEXMAB study has shown positive data.

Read more
29 Jun 2023 18:55

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more
9 Jun 2023 14:34

TRADING UPDATES: Medica shareholders back takeover; Arecor optimistic

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.